Understanding HCV Nonresponse and Identifying Candidates for Retreatment
Source: New Management Strategies for HCV Nonresponders and Relapsers

Module

Mitchell L. Shiffman, MD, reviews the various types of virologic response in hepatitis C virus–infected patients treated with interferon and ribavirin-based regimens and explains how to identify patients who would be good candidates for retreatment if they fail to achieve sustained virologic response.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Specify standard definitions of response and nonresponse to hepatitis C virus therapy
  • Discuss factors associated with nonresponse to hepatitis C virus therapy
  • Report criteria that may help to identify nonresponders who are good candidates for retreatment
  • Summarize data from studies of different retreatment strategies
  • Describe appropriate virologic goals of therapy for nonresponders undergoing retreatment

Topics covered include:

  • Introduction
  • Defining the Patterns of Virologic Response and Nonresponse
  • Rapid Virologic Response
  • Achieving Undetectable HCV RNA After Week 4 and Slow Virologic Response
  • Early Virologic Response and Nonresponse Virologic Patterns
  • Breakthrough and Relapse
  • Identifying Candidates for Retreatment: Null Response
  • Identifying Candidates for Retreatment: Partial Virologic Response
  • Identifying Candidates for Retreatment: Noncompliance, Medication Errors and Dose Reduction
  • Identifying Candidates for Retreatment: Failure to Recognize That Virologic Response Has Occurred
  • Identifying Candidates for Retreatment: Insufficient Treatment Duration
  • Conclusions
  • Summary of Clinical Implications
 

Faculty

  • Mitchell L. Shiffman
    MD

Credit Information

  • Release Date:
    October 04, 2007
  • Expiration Date:
    October 03, 2008
  • Physicians:
    maximum of 1.0 AMA PRA Category 1 Credit
  • Registered Nurses:
    1.0 Nursing contact hour
  • Are New HCV Therapies Ready for Use in Transplant Patients?

    Paul Y. Kwo MD - 7/10/2014    2 comments / Last Comment: 7/25/2014
    Paul Y. Kwo, MD, introduces some of the topics that will be discussed in an upcoming symposium in San Francisco.
  • Post-EASL Update: Reconsidering Whether to Treat Genotype 1 HCV Patients or Wait for All-Oral Therapy

    Paul Y. Kwo MD - 5/12/2014    1 comment / Last Comment: 5/23/2014
    Following the presentation of phase III data on new all-oral regimens for genotype 1 HCV at EASL, which patients might wait for the approval of new therapies and which should be treated now?
  • Genotype 1 HCV–Infected Cirrhotic Patients: Still Hard to Treat?

    Mark S. Sulkowski MD - 6/27/2014    2 comments / Last Comment: 7/25/2014
    After a long wait, the great majority of cirrhotic patients now has a realistic chance of achieving HCV cure.
  • Post-EASL Update: How I Manage HCV Patients for Whom First-Generation Protease Inhibitors Failed

    Stefan Zeuzem MD - 5/19/2014    2 comments / Last Comment: 5/26/2014
    Following new data from the ION-2 study reported at EASL 2014, options for retreatment of patients with previous PI failure appear much improved.
  • Post-EASL Update: What Is the Role of Treatment Guidelines in the Current HCV Era?

    Jordan J. Feld MD, MPH - 5/22/2014    4 comments / Last Comment: 7/4/2014
    With the new era of HCV therapies comes a new era in clinical guidelines; although there is certainly overlap, the major guidelines serve different but important roles.